Visualization of risk-area myocardium as a high-intensity, hyperenhanced "hot spot" by myocardial contrast echocardiography following coronary reperfusion
Quantitative analysis
Hideki Kunichika, MD, PhD*,
Barry Peters, MD*,
Bruno Cotter, MD*,
Hisashi Masugata, MD*,
Naomi Kunichika, MD, PhD*,
Paul L. Wolf, MD* and
Anthony N. DeMaria, MD, MACC*,*
* Division of Cardiology, University of California at San Diego, San Diego, California, USA. Dr. DeMaria has received grants and has been a sponsored speaker or occasional ad hoc consultant both for Bracco Pharmaceuticals, the manufacturer of BR-14, and virtually all other ultrasound contrast manufacturers. A. Jamil Tajik, MD, FACC, acted as the Guest Editor for this paper
View larger version (19K):
[in a new window]
|
Figure 1 Delayed myocardial contrast echocardiography (MCE) imaging (top) and time of events of the protocol (bottom). MBF = myocardial blood flow.
|
|
View larger version (141K):
[in a new window]
|
Figure 2 Short-axis myocardial contrast echocardiography images with BR-14 at baseline (A), during coronary occlusion with BR-1 (B) and BR-14 (C), and during coronary reperfusion with BR-14 (D). Part D shows acoustic enhancement of the risk-area myocardium as a "hot spot" during coronary reperfusion.
|
|
View larger version (16K):
[in a new window]
|
Figure 3 Correlation between the size of the myocardial region showing increased intensity with BR-14 during reperfusion and the risk-area myocardium identified by blue dye.
|
|
View larger version (12K):
[in a new window]
|
Figure 4 Relationship between the myeloperoxidase stain score and myocardial contrast echocardiography signal intensity in the risk area at 2-h reperfusion.
|
|
|
